2 results
Approved WMOPending
The objective of this phase-3 randomized study, with a double-blind treatment period of 8 weeksduration is to evaluate the efficacy and safety of the fixed dose combinations of TAK-491 pluschlorthalidone (40/12.5 mg and 40/25 mg) in subjects with…
Approved WMORecruiting
Primary Objective:The primary objective is to compare the incidence of drug-related Grade 3 - 5 AEs of N3I1 to N1I3 in subjects with previously untreated, unresectable or metastatic melanoma.Secondary Objective:• To evaluate the ORR, as determined…